13-cis-retinoic acid and interferon-α(2a) therapy in locally advanced squamous cell carcinoma of the cervix: p53 alteration, proliferating cell nuclear antigen expression and angiogenesis response

Journal of Obstetrics and Gynaecology Research

Volumn 24, Issue 5, 1998, Pages 335-341

  Charuruks, Navapun ^a   Voravud, Narin ^a   Termrungruanglert, Wichai ^a   Lertsanguansinchai, Prasert ^a   Tresukosol, Damrong ^a   Niruthisard, Somchai ^a   Sirisabya, Nakorn ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Biomarkers; Cervical carcinoma; Interferon; Isotretinoin

Indexed keywords

ALPHA2A INTERFERON; ANTIBODY; ANTIGEN; CYCLINE; ISOTRETINOIN; PROTEIN P53; TUMOR MARKER;

ADULT; ADVANCED CANCER; ANGIOGENESIS; ARTICLE; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROVASCULARIZATION; ORAL DRUG ADMINISTRATION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION; UTERINE CERVIX CARCINOMA;

EID: 0031790632     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.1998.tb00105.x     Document Type: Article

References (21)

1. Vatanasapt N, Martin H, Sriplung K, Chindavijak K, Sontipong S, Sriamporn S, Parkin DM, Ferlay J. Cancer incidence in Thailand, 1988-1991. Cancer Epidermiol Biomarkers Prevention 1995; 4: 475-483
2. Averett HE, LaPlatney DR, Little WA. Current role of radical hysterectomy as primary therapy for invasive carcinoma of the cervix. Am J Obstet Gynecol 1969; 105: 79-89
3. Jampolis S, Andras EJ, Fletcher GH. Analysis of sites and causes of failure of irradiation in invasive squamous cell carcinoma of the intact uterine cervix. Radiology 1975; 115: 681-685
4. World Health Organization. Control of cancer of the cervix uteri. Bull World Health Organ 1986; 64: 607-618
5. Lippman SM, Kessler JF, Meyskens FL Jr. Retinoids as preventive and therapeutic agents. Part I. Cancer Treat Rep 1987; 71: 391-405
6. Lippman SM, Shin DM, Lee J, Batsakis JG, Lotan R, Tainsky MA, Hittleman WN, Hong WK. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 1995; 55: 16-19
7. Spiegel RJ. The alpha interferons: Clinical overview. Semin Oncol 1987; 14 (suppl 2): 1-12
8. 2a: high active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992; 84: 241-245
9. Coltran RS, Kumar V, Robbins S, Schoen FJ. Neoplasia. In: Coltran RS, Kumar V, Robbins S, Schoen FJ, eds. Robbins, Pathologic Base of Disease. 5th ed. Philadelphia: WB Saunders, 1994: 241-303
10. Charuruks N, Voravud N. Molecular biology of head and neck tumorigenesis: The role of p53 expression and genetic instability. J Med Assoc Thai 1996; 79 (suppl 1): S3-10
11. Inagaki T, Ebisuno S, Uekado Y, Hirano A, Hiroi A, Shinks T, Ohkawa T. PCNA and p53 in urinary bladder cancer: Correlation with histological findings and prognosis. Internl J Urol 1997; 4: 172-177
12. Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120-1124
13. Concill C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer 1990; 65: 1864-1866
14. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasikimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989; 86: 8763-8767
15. Shin DM, Voravud N, Ro JY, Lee JS, Hong WK, Hittelman WN. Sequential increases in proliferating cell nuclear antigen expression in head and neck tumorigenesis: A potential biomarker. J Natl Cancer Inst 1993; 85: 971-978
16. Esrig D, Spruck III CH, Nichols PW, Chaiwun B, Steven K, Groshen SC, Skinner DG, Jones PA, Cote RJ. p53 Nuclear protein accumulation correlates with mutation in p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 1389-1397
17. Chang F, Syrjanen K. Implication of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995; 1: 1009-1022
18. Oka K, Nakano T, Arai T. p53 CM1 expression is not associated with prognosis in uterine and cervical carcinoma. Cancer 1993; 72: 160-164
19. Paquette RL, Lee YY, Wilczynski SP, Karmakar A, Kizaki M, Miller CW, Koeffler HP. Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 1993; 72: 1272-1280
20. Folkman J. What is the evidence that tumors are angiogenesis dependent? (editorial). J Natl Cancer Inst 1990; 82: 4-6
21. Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, Harris AL. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Nat Cancer Inst 1997; 89: 1044-1049